Volume 53 | Number 4 | August 2018

Abstract List

Christopher T. Chen M.D., Ling Li M.S.P.H., Gabriel Brooks M.D., M.P.H., Michael Hassett M.D., M.P.H., Deborah Schrag M.D., M.P.H.


To characterize spending patterns for Medicare patients with incident breast, prostate, lung, and colorectal cancer.

Data Sources/Study Setting/Study Design

2007–2012 data from the Surveillance, Epidemiology, and End Results Program linked with Medicare fee‐for‐service claims.

Data Collection/Extraction Methods

We calculate per‐patient monthly and yearly mean and median expenditures, by cancer type, stage at diagnosis, and spending category, over the years of diagnosis and death.

Principal Findings

Over the year of diagnosis, mean spending was $35,849, $26,295, $55,597, and $63,063 for breast, prostate, lung, and colorectal cancer, respectively. Over the year of death, spending was similar across different cancer types and stage at diagnosis.


Characterization of Medicare spending according to clinically meaningful categories may assist development of oncology alternative payment models and cost‐effectiveness models.